-->

Company Registry

Lacerta Therapeutics Inc
Profile last edited on: 8/29/2019

Gene therapy
Year Founded
2017
First SBIR Year
2018
Latest SBIR Award
2020
Program Status
Active

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

12085 Research Drive Suite 46
Alachua, FL 32615
   (352) 275-7915
   N/A
   www.lacertatherapeutics.com
Multiple Locations:   
Congressional District:   03
County:   Alachua

Public Profile

Lacerta Therapeutics, Inc. is a clinical-stage gene therapy company developing treatments for central nervous system and lysosomal storage diseases using a constellation of adeno-associated virus (AAV) vector technologies. In August 2018, Sarepta Therapeutics Inc. (NASDAQ:SRPT) - formerly dba AVI BioPharma- and itself an SBIR-involved firm until 2008 - licensed exclusive worldwide rights to Lacerta Therapeutics Inc.'s gene therapy candidate for Pompe disease - an autosomal recessive metabolic disorder which damages muscle and nerve cells. Paying an initial $30M to the smaller firm, Sarepta also has options to license two additional neuro-focused candidates from Lacerta's pipeline.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
---
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
2020 2 NIH $2,456,333
Targeting Glioblastoma Stem-Like Cells with Custom-Designed Viral Vectors

Key People / Management

  Joseph Reddy -- President & Chief Executive Office

  Edgardo Rodriguez-Lebron -- dgardo Rodríguez-Lebrón, PhD Chief Scientific Officer

  Ken Warrington -- Founder and CTO

SBIR firms in the news

There are no news available.